Jefferies (NYSE:JEF) analyst Stephanie Wissink maintained a Buy rating on Medifast (NYSE:MED) Inc on Tuesday, setting a price target of $295, which is approximately 28.26% above the present share price of $230.01.
Wissink expects Medifast Inc to post earnings per share (EPS) of $2.38 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Medifast, with an average price target of $302.33.
The analysts price targets range from a high of $310 to a low of $295.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $264.91 million and a net profit of $37.97 million. The company's market cap is $2.71 billion.
According to TipRanks.com, Jefferies analyst Stephanie Wissink is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 5.0% and a 54.44% success rate.
Medifast, Inc. is a health and wellness company, which engages in the manufacture and distribution of healthy living products and programs. Its product lines include weight loss, weight management and healthy living meal replacements, snacks, hydration products, and vitamins. The company was founded by William Vitale in 1980 and is headquartered in Baltimore, MD.